Patents for A61P 35 - Antineoplastic agents (221,099)
02/2002
02/07/2002CA2405728A1 Lipid-peptide conjugates for treatment of cancer
02/07/2002CA2388550A1 Dispersions for formulating slightly or poorly soluble active ingredients
02/07/2002CA2385910A1 Somatostatin analogs for the treatment of cancer
02/06/2002EP1178115A2 Phosphodiesterase
02/06/2002EP1177796A1 Preventives/remedies for liver diseases
02/06/2002EP1177795A2 Use of ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
02/06/2002EP1177791A2 Use of glycogen phosphorylase inhibitors to inhibit tumor growth
02/06/2002EP1177790A1 Therapy with cannabinoids in the treatment of cerebral tumor
02/06/2002EP1177312A2 Human gil-19/ae289 proteins and polynucleotides encoding same
02/06/2002EP1177297A2 Novel nucleic acids and proteins with growth hormone activity
02/06/2002EP1177296A2 Extracellular matrix and adhesion-associated proteins
02/06/2002EP1177288A1 Tumour-associated antigen
02/06/2002EP1177286A1 Mdm interacting protein and methods of use thereof
02/06/2002EP1177208A1 Spray drying of thrombin inhibitors
02/06/2002EP1177197A2 Polyamines and their use in therapy
02/06/2002EP1177195A1 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
02/06/2002EP1177186A1 Ureas and their use as cell adhesion modulators
02/06/2002EP1177185A1 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents
02/06/2002EP1177183A1 Hydroxamic and carboxylic acid derivatives
02/06/2002EP1177181A1 Substituted bicyclic compounds
02/06/2002EP1177178A1 Heterocyclically substituted benzimidazoles, the production and application thereof
02/06/2002EP1177175A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
02/06/2002EP1177174A1 Hydroxamic and carboxylic acid derivatives
02/06/2002EP1177173A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
02/06/2002EP1177168A1 Caspase inhibitors and the use thereof
02/06/2002EP1176988A1 Radioactive cisplatin in the treatment of cancer
02/06/2002EP1176986A1 Differentiation of monocytes into functional dendritic cells
02/06/2002EP1176985A2 Enzymatically activated polymeric drug conjugates
02/06/2002EP1176984A2 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
02/06/2002EP1176981A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
02/06/2002EP1176975A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
02/06/2002EP1176972A1 Use of phyllanthus for targeted stimulation of the immune system
02/06/2002EP1176971A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
02/06/2002EP1176968A2 Selenium-containing pro-drugs for cancer therapy
02/06/2002EP1176965A1 Antisense modulation of fas mediated signaling
02/06/2002EP1176964A1 Compositions and uses of et743 for treating cancer
02/06/2002EP1176957A1 Method for treating abnormal cell proliferation in the brain
02/06/2002EP1176956A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
02/06/2002EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor
02/06/2002EP0891325B1 Para-substituted phenylpropanoic acid derivatives as integrin antagonists
02/06/2002EP0866865B1 Chimeric oligomers having an rna-cleavage activity
02/06/2002EP0845991B1 Use of phenol substituted diphosphonates as antineoplastic agents
02/06/2002EP0836605B1 Pyrrolopyrimidines and processes for the preparation thereof
02/06/2002EP0774973B1 Treatment of cancer with human chorionic gonadotropin
02/06/2002EP0729354B1 Farnesyl derivatives and pharmaceutical compositions containing them
02/06/2002EP0679081B1 Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation
02/06/2002CN1334878A Polynucleotide comprising ubiquitous chromatin opening element (UCDE)
02/06/2002CN1334875A Cell signalling polypeptides and nucleic acids
02/06/2002CN1334820A Connective tissue growth factor fragments and methods and uses thereof
02/06/2002CN1334819A Connective tissue growth factor fragments and methods and uses thereof
02/06/2002CN1334815A Methotrexate derivatives
02/06/2002CN1334811A Tricyclic farnesyl protein transferase inhibitors
02/06/2002CN1334809A Nonsteroidal antiinflammatories
02/06/2002CN1334807A 1-heterocycle substd. diarylamines
02/06/2002CN1334806A Beta-amide and beta-sulfonamide carboxylic acid derivs., their preparation and their use as endothelin receptor antagonists
02/06/2002CN1334801A Biphenyl and biphenyl-analogous compounds as integrin antagonists
02/06/2002CN1334798A Phenylglycine derivatives
02/06/2002CN1334797A 3,4-diamino-3-cyclobutene-1,2-dione derivs. which inhibit leukocyte adhesion mediated by VLA-4
02/06/2002CN1334742A Method of using lanreotide as somatostatin analogue
02/06/2002CN1334730A Vitronectin receptor antagonist
02/06/2002CN1334728A Palladium-substd. bacteriochlorophll derivatives and use thereof
02/06/2002CN1334726A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists
02/06/2002CN1334343A Antibody for suppressing tumor growth, its derivative and its application
02/06/2002CN1334107A Medicine for treating cancer
02/05/2002US6344571 Therapy for mammary or colon tumors
02/05/2002US6344562 Thiazole derivatives
02/05/2002US6344551 Contulakin-G, analogs thereof and uses therefor
02/05/2002US6344544 Semaphorin-specific antibodies
02/05/2002US6344541 DKR polypeptides
02/05/2002US6344484 Treatment of tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis
02/05/2002US6344475 Cystic fibrosis
02/05/2002US6344465 Inhibitors of IMPDH enzyme
02/05/2002US6344463 Skin disorders, acne
02/05/2002US6344459 Treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis
02/05/2002US6344455 Treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis
02/05/2002US6344450 Lactam compounds and their use as inhibitors of serine proteases and method
02/05/2002US6344447 Administering mixture of nucleosides; anticancer agent
02/05/2002US6344441 Lipoprotein-regulating medicaments
02/05/2002US6344339 Monoclonal antibodies against the extracellular domain of human VEGF-receptor protein (KDR)
02/05/2002US6344321 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
02/05/2002US6344203 Mimicking peptides in cancer therapy
02/05/2002US6344195 Administering reovirus to a ras-mediated neoplasm
02/05/2002CA2150714C Syndecan stimulation of cellular differentiation
02/05/2002CA2098113C Substances of polypeptide nature useful in human therapy
02/05/2002CA2051418C Novel vitamin d analogues
02/05/2002CA2051288C Viral targeted destruction of neoplastic cells
01/2002
01/31/2002WO2002008716A2 Method for screening peptides for use in immunotherapy
01/31/2002WO2002008475A2 Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching
01/31/2002WO2002008399A2 Human kinases
01/31/2002WO2002008396A2 Human proteases
01/31/2002WO2002008294A1 Diagnosis and treatment of hhv-8 associated diseases based on the hhv-8 coded chemokine receptor
01/31/2002WO2002008293A2 Multivalent target binding protein
01/31/2002WO2002008291A2 Multi-specific reagent for selective stimulation of cell surface receptors
01/31/2002WO2002008287A2 Nk cells activating receptors and their therapeutic and diagnostic uses
01/31/2002WO2002008286A2 Zinc finger domain recognition code and uses thereof
01/31/2002WO2002008285A2 Il-17 molecules and uses thereof
01/31/2002WO2002008284A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
01/31/2002WO2002008281A2 Bstp-cad protein and related reagents and methods of use thereof
01/31/2002WO2002008263A2 Modified virus having an altered tropism
01/31/2002WO2002008256A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus